Loading
Life sciences · Journal article
JCO Oncology Practice · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Purpose Local therapy (LT) for metastatic colorectal cancer (mCRC) is recommended when eradicating all metastases is feasible. Although LT is widely used, its population-level impact remains unclear. This study aims to use real-world population-based data to assess LT utilization and survival trends in mCRC. Methods Patients diagnosed with mCRC from 2010 to 2023 were included, using data from the Cancer Registry of Norway and the Norwegian Patient Registry. LT was defined as surgery, stereotactic radiotherapy (SRT), or ablation targeting liver, lung, or brain metastases. Outcomes were reported as median overall survival (OS) and 2-, 5-, and 10-year OS. The effect of the first versus last time period on survival was assessed using univariable and multivariable Cox regression. Results Among 64,112 CRC cases, 20,210 had mCRC. Of these, 21% received LT, 39% systemic therapy only, 12% other therapies, and 29% no therapy. Metastasectomy was the primary LT (87%), whereas SRT use was limited. LT use increased by 12% annually from 2010 to 2015 and then stabilized. The overall mCRC survival improved, with the 5-year OS increasing from 16% to 23% and the median OS from 15 to 18 months (adjusted hazard ratio, 0.92; 95% CI, 0.89 to 0.95). No significant survival improvement was observed between time periods in the LT or systemic therapy only subgroups. The 5-year OS for patients receiving LT for liver, lung, and brain metastases was 50%, 62%, and 5%, respectively. Conclusion LT utilization increased, with outcomes comparable with more selected populations. Survival in treatment subgroups remained stable over time, but improved in the overall mCRC population, suggesting that the population-level gains may reflect changes in treatment allocation rather than improvements within modalities.